Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease
Clinical trial NCT07625384 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07625384
- Sponsor
- R-Pharm International, LLC
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-18
- Primary completion
- 2027-12-14
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.